Abstract
Abstract
Objective
HAART had significantly improved the quality of life of HIV patients. However, it results different adverse effects such as: hepatotoxicity, nephrotoxicity, lipodystrophy, anemia, diarrhea, psychiatric disorder and others. Therefore, this comparative cross sectional study was designed to investigate liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital.
Result
A total of 152 individuals (76 cases and 76 controls) were included in this study. The mean ages of treatment and control groups were 37.37 and 36.38 respectively. The mean values of liver enzymes (ALT, AST and ALP), total bilirubin and direct bilirubin were significantly higher (p < 0.05) while, total protein and creatinine were significantly lower in patients taking HAART compared with treatment naïve controls. In this study, about 19 (25%) of clients in HAART treated groups and 7 (9.2%) of treatment naïve controls had showed liver enzyme changes. Moreover, 23.7% and 1.3% of the HAART treated groups developed mild and moderate liver enzyme elevation or hepatotoxicity, respectively. In this study, significant difference was observed in liver enzyme elevation between ART and pre-ART patients. As a result, regular clinical and laboratory monitoring of liver function will be necessary to prevent severe form of liver injury.
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference37 articles.
1. Khan K, Khan A, Sulaiman S, Soo C, Aftab R. Adverse effect of highly active anti-retroviral therapy (HAART) in HIV/AIDS patients. Indian J Pharm Pract. 2014.
https://doi.org/10.5530/ijopp.7.3.7
.
2. Federal HIV/AIDS Prevention and Control Office and Federal Ministry of Health (FHAPCO). Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia. 2008. p. 77–80:
http://www.who.int/hiv/pub/guidelines/ethiopia_art
.
3. Pol S, Lebray P, Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis. 2004.
https://doi.org/10.1086/381499
.
4. Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35(1):182–9.
https://doi.org/10.1053/jhep.2002.30319
.
5. Shepard K. Clarification of risk factors for severe, life threatening and fatal hepatotoxicity with Viramune (nevirapine) [letter]. Rigdefield: Boehringer Ingelheim Pharmaceuticals; 2004.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献